Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL9747772 | 0.98 | LMNA (0.75) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL3645 | 0.98 | LMNA (0.75) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL3934174 | 0.87 | LMNA (0.95) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL3934178 | 0.87 | LMNA (0.95) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL165161 | 0.85 | LMNA (1.00) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL21647917 | 0.85 | LMNA (1.00) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL29777368 | 0.85 | LMNA (1.00) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL5313046 | 0.85 | LMNA (1.00) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL255601 | 0.85 | LMNA (1.00) | LMNAMAPK1SRCCES2CES1 | |
| Mandelic Acid SCHEMBL1050 | 0.85 | LMNA (1.00) | LMNAMAPK1SRCCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10092542-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORPORATION (US) | 2018-10-09 | — | — | US | claimed |
| US-20170281597-A1 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | AMGEN INC. | 2017-10-05 | — | — | US | claimed |
| US-20150290171-A1 | METHODS FOR THE TREATMENT OF BONE LOSS | CELGENE CORPORATION | 2015-10-15 | — | — | US | claimed |
| EP-2916869-A1 | METHODS FOR THE TREATMENT OF BONE LOSS | Celgene Corporation (US) | 2015-09-16 | — | — | EP | claimed |
| WO-2014074846-A1 | METHODS FOR THE TREATMENT OF BONE LOSS | CELGENE CORPORATION (US) | 2014-05-15 | — | — | WO | claimed |
| EP-2097137-B1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES. | MOKWALO SPF S A (LU) | 2012-09-19 | — | — | EP | claimed |
| US-8101564-B2 | Methods for regulating osteoclast differentiation and bone resorption using LRRc17 | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-01-24 | — | — | US | claimed |
| US-7576053-B2 | treating osteoporosis caused by imbalance of osteoclast and osteoblast activity, glandular disorders with a Syk kinase inhibitor a 2,4-pyrimidinediamine compound; alendronate, calcitonin, estrogen and selective estrogen receptor modulators; side effect reduction | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20090104203-A1 | Compositions and Methods for Regulating Osteoclast Differentiation, Activation and Bone Resorption | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2009-04-23 | — | — | US | claimed |
| EP-1896134-A2 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE BONE DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2007130619-A1 | COMPOSITIONS AND METHODS FOR REGULATING OSTEOCLAST DIFFERENTIATION, ACTIVATION AND BONE RESORPTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070004626-A1 | Methods and compositions for treating degenerative bone disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | US | claimed |
| WO-2006135915-A2 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE BONE DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | WO | claimed |
| US-10149824-B2 | Reverse hexagonal mesophases (HII) and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-12-11 | — | — | US | disclosed |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VIDASYM, LLC | 2018-11-15 | — | — | US | disclosed |
| EP-2498754-B1 | REVERSE HEXAGONAL MESOPHASES (H II) AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2018-06-06 | — | — | EP | disclosed |
| US-20070004626-A1 | Methods and compositions for treating degenerative bone disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| CN-1887294-A | Orally taken liquid medicine composition containing strontium | HENAN FUREN PHARMACEUTICAL IND (CN) | 2007-01-03 | — | — | CN | disclosed |
| WO-2006135915-A2 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE BONE DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| CN-1858049-A | Synthetic method for strotium renelate intermediate | UNIV HEBEI MEDICAL (CN) | 2006-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281597-A1 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | PDE4A, PDE2A, PDE4B | LMNA 1944/4885MAPK1 1206/4885SRC 4455/4885 |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VDR, CYP2R1, CYP24A1 | LMNA 3373/4885MAPK1 1618/4885SRC 2259/4885 |
| US-20150290171-A1 | METHODS FOR THE TREATMENT OF BONE LOSS | SOST, COL2A1, BMP2 | LMNA 606/4885MAPK1 2442/4885SRC 2321/4885 |
| US-20070004626-A1 | Methods and compositions for treating degenerative bone disorders | SYK, TRAF6, BTK | LMNA 1133/4885MAPK1 911/4885SRC 16/4885 |
| US-10092542-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | PDE4A, PDE2A, PDE4B | LMNA 1944/4885MAPK1 1206/4885SRC 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.